## Abstract Metastatic renal cell carcinomas (MRCC) are considered as immunogeneic tumors on the basis of the clinical responses observed in patients treated by ILβ2. However, renal cell carcinoma patients are also characterized by alterations of the immune response that may compromise the immunoth
β¦ LIBER β¦
The cellular and molecular basis of natural antitumor immunity in renal cell carcinoma patients
β Scribed by Dolores J. Schendel; C. S. Falk; B. Frankenberger; E. Noessner; J. Schleypen; H. Pohla
- Publisher
- Springer
- Year
- 2004
- Tongue
- German
- Weight
- 341 KB
- Volume
- 43
- Category
- Article
- ISSN
- 0340-2592
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Analysis of the natural killer mediated
β
Asma Gati; Sylvie Da Rocha; Nadia Guerra; Bernard Escudier; Alessandro Moretta;
π
Article
π
2004
π
John Wiley and Sons
π
French
β 394 KB
π 1 views
Clinicopathologic and molecular correlat
β
John S. Lam; Oleg Shvarts; Jonathan W. Said; Allan J. Pantuck; David B. Seligson
π
Article
π
2005
π
John Wiley and Sons
π
English
β 164 KB
π 1 views
Clinical studies on cell-mediated immuni
β
Shinichi Ikemoto; Seiji Wada; Masato Kamizuru; Nobuyuki Hayahara; Taketoshi Kish
π
Article
π
1992
π
Springer-Verlag
π
English
β 495 KB
Autoimmune basis for visual paraneoplast
β
Gerald B. Grunwald; Steven E. Kornguth; Javad Towfighi; Joseph Sassani; Mary A.
π
Article
π
1987
π
John Wiley and Sons
π
English
β 857 KB
Analysis of the immune reactivity of inf
β
Ursula ElsΓ€sser-Beile; Ulrich Wetterauer; Wolfgang Schultze-Seemann; Harald Gall
π
Article
π
1996
π
Springer-Verlag
π
English
β 115 KB
Prognostic relevance of the mTOR pathway
β
Allan J. Pantuck; David B. Seligson; Tobias Klatte; Hong Yu; John T. Leppert; La
π
Article
π
2007
π
John Wiley and Sons
π
English
β 980 KB
## Abstract ## BACKGROUND. The mammalian target of rapamycin (mTOR) pathway is upβregulated in many human cancers, and agents targeting the mTOR pathway are in various stages of clinical development. The goal of the study was to evaluate the potential and limitations of targeting the mTOR pathway